Cargando…
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
BACKGROUND: Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals (DAAs) and patient prognosis. Non-invasive techniques to assess liver fibrosis are becoming important. Recently, serum Mac-2 binding protein glycosylation isomer (M2BPGi) was identified as a non...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284180/ https://www.ncbi.nlm.nih.gov/pubmed/32550761 http://dx.doi.org/10.3748/wjg.v26.i21.2864 |
_version_ | 1783544409105629184 |
---|---|
author | Saleh, Shereen A Salama, Mohamed M Alhusseini, Marwan M Mohamed, Ghada A |
author_facet | Saleh, Shereen A Salama, Mohamed M Alhusseini, Marwan M Mohamed, Ghada A |
author_sort | Saleh, Shereen A |
collection | PubMed |
description | BACKGROUND: Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals (DAAs) and patient prognosis. Non-invasive techniques to assess liver fibrosis are becoming important. Recently, serum Mac-2 binding protein glycosylation isomer (M2BPGi) was identified as a non-invasive marker of liver fibrosis. AIM: To investigate the diagnostic accuracy of M2BPGi in assessing liver fibrosis in patients with chronic hepatitis C (CHC) treated with DAAs. METHODS: From December 2017 to August 2018, 80 treatment-naïve adult patients with CHC who were eligible for DAAs therapy were consecutively enrolled in this observational cohort study. For 12 weeks, 65 patients were treated with sofosbuvir/daclatasvir, and 15 patients were treated with sofosbuvir/daclatasvir and a weight-based dose of ribavirin at knowledge and technology association for hepatitis C management clinic, Cairo, Egypt. We measured serum M2BPGi levels, PAPAS index, fibrosis-4 (FIB-4) score and liver stiffness measurements (LSM) at baseline and 12 weeks after the end of treatment. Serum M2BPGi levels were measured using enzyme-linked immunosorbent assay. RESULTS: All patients achieved sustained virologic response (SVR12) (100%). Serum M2BPGi levels, LSM, FIB-4 score and PAPAS index decreased significantly at SVR12 (P < 0.05). Serum M2BPGi levels correlated positively with LSM at baseline and SVR12 (P < 0.001). At baseline, compared with the FIB-4 score and PAPAS index, M2BPGi was the best marker to distinguish patients with grade F4 fibrosis (AUC = 0.801, P < 0.001), patients with grade F2 from grade F0-1 fibrosis (AUC = 0.713, P = 0.012), patients with grade F3-4 from grade F0-2 fibrosis (AUC = 0.730, P < 0.001), and patients with grade F2-4 from grade F0-1 fibrosis (AUC = 0.763, P < 0.001). At SVR12, M2BPGi had the greatest AUCs for differentiating patients with grade F4 fibrosis (AUC = 0.844, P < 0.001), patients with grade F3 from grade F0-2 fibrosis (AUC = 0.893, P = 0.002), patients with grade F3-4 from grade F0-2 fibrosis (AUC = 0.891, P < 0.001), and patients with grade F2-4 from grade F0-1 fibrosis (AUC = 0.750, P < 0.001). CONCLUSION: M2BPGi is a reliable marker for the non-invasive assessment and prediction of liver fibrosis regression in patients with CHC who achieved an SVR with DAAs therapy. |
format | Online Article Text |
id | pubmed-7284180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-72841802020-06-17 M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals Saleh, Shereen A Salama, Mohamed M Alhusseini, Marwan M Mohamed, Ghada A World J Gastroenterol Observational Study BACKGROUND: Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals (DAAs) and patient prognosis. Non-invasive techniques to assess liver fibrosis are becoming important. Recently, serum Mac-2 binding protein glycosylation isomer (M2BPGi) was identified as a non-invasive marker of liver fibrosis. AIM: To investigate the diagnostic accuracy of M2BPGi in assessing liver fibrosis in patients with chronic hepatitis C (CHC) treated with DAAs. METHODS: From December 2017 to August 2018, 80 treatment-naïve adult patients with CHC who were eligible for DAAs therapy were consecutively enrolled in this observational cohort study. For 12 weeks, 65 patients were treated with sofosbuvir/daclatasvir, and 15 patients were treated with sofosbuvir/daclatasvir and a weight-based dose of ribavirin at knowledge and technology association for hepatitis C management clinic, Cairo, Egypt. We measured serum M2BPGi levels, PAPAS index, fibrosis-4 (FIB-4) score and liver stiffness measurements (LSM) at baseline and 12 weeks after the end of treatment. Serum M2BPGi levels were measured using enzyme-linked immunosorbent assay. RESULTS: All patients achieved sustained virologic response (SVR12) (100%). Serum M2BPGi levels, LSM, FIB-4 score and PAPAS index decreased significantly at SVR12 (P < 0.05). Serum M2BPGi levels correlated positively with LSM at baseline and SVR12 (P < 0.001). At baseline, compared with the FIB-4 score and PAPAS index, M2BPGi was the best marker to distinguish patients with grade F4 fibrosis (AUC = 0.801, P < 0.001), patients with grade F2 from grade F0-1 fibrosis (AUC = 0.713, P = 0.012), patients with grade F3-4 from grade F0-2 fibrosis (AUC = 0.730, P < 0.001), and patients with grade F2-4 from grade F0-1 fibrosis (AUC = 0.763, P < 0.001). At SVR12, M2BPGi had the greatest AUCs for differentiating patients with grade F4 fibrosis (AUC = 0.844, P < 0.001), patients with grade F3 from grade F0-2 fibrosis (AUC = 0.893, P = 0.002), patients with grade F3-4 from grade F0-2 fibrosis (AUC = 0.891, P < 0.001), and patients with grade F2-4 from grade F0-1 fibrosis (AUC = 0.750, P < 0.001). CONCLUSION: M2BPGi is a reliable marker for the non-invasive assessment and prediction of liver fibrosis regression in patients with CHC who achieved an SVR with DAAs therapy. Baishideng Publishing Group Inc 2020-06-07 2020-06-07 /pmc/articles/PMC7284180/ /pubmed/32550761 http://dx.doi.org/10.3748/wjg.v26.i21.2864 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Observational Study Saleh, Shereen A Salama, Mohamed M Alhusseini, Marwan M Mohamed, Ghada A M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title_full | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title_fullStr | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title_full_unstemmed | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title_short | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals |
title_sort | m2bpgi for assessing liver fibrosis in patients with hepatitis c treated with direct-acting antivirals |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284180/ https://www.ncbi.nlm.nih.gov/pubmed/32550761 http://dx.doi.org/10.3748/wjg.v26.i21.2864 |
work_keys_str_mv | AT salehshereena m2bpgiforassessingliverfibrosisinpatientswithhepatitisctreatedwithdirectactingantivirals AT salamamohamedm m2bpgiforassessingliverfibrosisinpatientswithhepatitisctreatedwithdirectactingantivirals AT alhusseinimarwanm m2bpgiforassessingliverfibrosisinpatientswithhepatitisctreatedwithdirectactingantivirals AT mohamedghadaa m2bpgiforassessingliverfibrosisinpatientswithhepatitisctreatedwithdirectactingantivirals |